Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The EORTC 08062 phase II randomised trial investigated the activity and safety of single agent amrubicin, cisplatin combined with amrubicin, and cisplatin combined with etoposide as first line treatment in extensive disease (ED) small cell lung cancer (SCLC).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Eur. J. Cancer

Title: European journal of cancer (Oxford, England : 1990)

ISSN (Electronic): 1879-0852

ISSN (Print): 0959-8049

Publication date (Electronic): Oct 2011

Volume: 47

Issue: 15

Affiliations

[1 ] The Royal Marsden Hospital, Sutton, United Kingdom. mary.obrien@rmh.nhs.uk

Article

Publisher Item ID: S0959-8049(11)00353-4

DOI: 10.1016/j.ejca.2011.05.020

PubMed ID: 21684151

SO-VID: bf44cd34-358a-4b16-b7b4-e69051048e70

History

Data availability:

Comments

Comment on this article

scite_

0

Smart Citations

0

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 10

See all cited by